Abstract
Aim: to study the impact of COVID-19 on the course of bronchial asthma in children. Materials and methods. 45 children with asthma who suffered from COVID-19 were included in the study. The diagnosis of COVID-19 was confirmed by PCR-test or rapid antigen test. The age of the children was 5 to 17 years, the average age was 10.87 ± 1.34 years. Results. In 31.1% of examined children, COVID-19 was asymptomatic. After recovery from COVID-19, the frequency of asthma daytime symptoms increased by 3 times, being noted in 13.3% of children. The need to use short-term β2-agonists increased by 2.5 times, being recorded in 11.1% of patients. Most of the spirometry indicators were increased in children before COVID-19, but did not differ significantly in children of both groups (p > 0.05). A significant decrease in the MEF25 was noted in children after recovery from COVID-19 (70.72 ± 5.12 vs. 90.82 ± 9.94, p < 0.05). In patients after recovery from COVID-19, a positive postbronchodilator test (change of FEV1 ≥ 12.0%) was found more frequently (6.7% vs 15.5%), the average increase in FEV1 value was 1.4 times higher (5.14 ± 1.24 versus 7.32 ± 1.67, p > 0.05). Conclusion. COVD-19 in children with asthma had a mild or asymptomatic course. Collected data may suggest the impact COVID-19 on asthma control in children and appearance of bronchial hyperresponsiveness in post-COVID-19 period. Key words: asthma, children, COVID-19, asthma control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
